Table 1 ALK partners and chromosomal abnormalities leading to several ALK fusion proteins As TPM3-ALK fusion proteins interact with wild-type TPM3 and associate to the cytoskeleton (data not shown ...

1999; Tian et al., 1995). TPM3–ALK is expressed from a t(1;2)(q25;p23) translocation (Lamant et al., 1999). This translocation leads to the fusion of the N-terminal 221 residues of TPM3 to the ...

(D) ALK staining with ALK1 antibody. Restricted cytoplasmic staining with membrane reinforcement associated with the t(1;2)(q25;p23) translocation (expression of the TPM3-ALK protein; magnification, ...

Notable objective and sustained responses were observed in patients with ALK fusion-positive ALCL and IMT, establishing a precedent in pediatric oncology for studying the early-phase activity of a ...

The EML4 (echinoderm microtubule-associated protein-like 4)–ALK (anaplastic lymphoma kinase) fusion-type tyrosine kinase is an oncoprotein found in 4 to 5% of non–small-cell lung cancers ...

“Our findings confirm that a RANBP2-ALK fusion can act as a driver mutation in AML and that gilteritinib can be a clinically effective and well-tolerated ALK inhibitor and could be considered as ...

ALK alterations (fusion genes) occur in about 2% of NSCLC tumors, predominantly in younger nonsmokers. Alectinib is approved in advanced NSCLC with an ALK alteration based on improved efficacy and ...

ExoDx Lung(ALK) detects EML4-ALK fusion transcripts with the goal of informing individualized treatment decisions for patients. ExoDx Lung(ALK) is now commercially available in the United States ...